A high prevalence of prediabetes is fuelling the evolving global diabetes pandemic, and optimisation of management of prediabetes is an urgent global clinical priority. |
A broad evidence base from clinical trials and previous clinical experience support the efficacy and safety profiles of metformin for diabetes prevention, and highlight subjects in which metformin will be most effective. |
Current evidence supports a role for metformin in diabetes prevention, given in addition to lifestyle intervention, in people with prediabetes. |
1 Introduction
2 Search Strategy
3 Characteristics of Prediabetes
3.1 Pathophysiology and Diagnosis of Prediabetes
-
impaired glucose tolerance (IGT), in which postprandial glucose control is impaired but fasting plasma glucose (FPG) is normal;
-
impaired fasting glucose (IFG), in which a chronic elevation of FPG occurs in the absence of a deterioration in postprandial glucose control.
Prediabetic state | FPG [mg/dL (mmol/L)] | 2-h plasma glucose [mg/dL (mmol/L)] |
---|---|---|
NGT | <100 (<5.6) | <140 (<7.8) |
IFG | 100–125 (5.6–6.9) | 140–199 (7.8–11.0) |
IGT | <126 (<6.9) | 140–199 (7.8–11.0) |
Combined IFG/IGT | 100–125 (5.6–6.9) | 140–199 (7.8–11.0) |
3.2 Prevalence of Prediabetes
3.3 Prediabetes and Adverse Clinical Outcomes
3.4 Principles of Management of Prediabetes
US (ADA) [4] | Europe (European multidisciplinary consortium) [32] | |
---|---|---|
Weight loss | 7 % of initial weighta
| 5–7 % of initial weight |
Exercise | 150 min/week of moderate exercisea
| 30 min/day of moderate exercise |
Diet | No specific recommendations, refer to intensive behavioural management to achieve the 7 % weight loss goal | ≥15 g fibre per 1000 kcal, ≤35 % of total energy as fat, <10 % of total energy as saturated fat or trans fat |
4 Overview of the Pharmacologic Properties of Metformin
4.1 Principal Therapeutic Sites of Action of Metformin
4.2 Molecular Mechanisms for the Antihyperglycaemic Actions of Metformin
4.3 Cardiovascular Actions of Metformin
4.4 Safety and Tolerability
5 Principal Diabetes Prevention Trials with Metformin
5.1 Overview
Trial | Design | Subjects |
N; duration (years) | Control group | Active treatments | % change in diabetes risk |
---|---|---|---|---|---|---|
Principal diabetes prevention trials that evaluated metformin | ||||||
DPP (US) [19] | RCT | IGT and high–normal glucose | 3234; 3 | Placebo plus standard lifestyle advice | Metformin plus standard lifestyle advice Intensive lifestyle intervention | −31 −58 |
DPP Outcome Study (US) [69] | O | Epidemiological follow-up to DPP | 2766; 5.7 | Placebo plus intensive lifestyle advice | Metformin 1700 mg/day + intensive lifestyle advice Intensive lifestyle advice | −13 +5 |
RCT | IGT | 531; 2.5 | Standard lifestyle advice | Metformin plus standard lifestyle advice Metformin plus intensive lifestyle intervention Intensive lifestyle intervention | −26 −28 −29 | |
Wenying et al. (China) [68] | NR | IGT | 321; 3 | Standard lifestyle advice | Metformin Acarbose Intensive lifestyle intervention | −88 −87 −43 |
Li et al. (China) [66] | RCT | IGT | 70; 1 | Placebo | Metformin | −66a
|
Iqbal Hydrie et al. (Pakistan) [67] | RCT | IGT | 317; 1.5 | Standard lifestyle advice | Metformin Intensive lifestyle intervention | −76.5 −71 |
CANOE (Canada) [64] | RCT | IGT | 207; 3.9 | Placebo | Metformin 500 mg plus rosiglitazone 2 mg twice daily | −66 |
Principal diabetes prevention trials that did not evaluate metformin | ||||||
Diabetes Prevention Study (Finland) [70] | RCT | IGT | 522; 3.2 | Standard lifestyle advice | Intensive, multifactorial lifestyle intervention | −58 |
Da Qing study (China) [71] | RBS | IGT | 577; 6 | Standard lifestyle advice | Diet, exercise, or both together | −31 to −46 |
RCT | IGT | 1429; 3.3 | Placebo | Acarbose | −25 | |
XENDOS (Sween) [74] | RCT | IGT and obesity | 694; 4c
| Placebo | Orlistat | −45 |
RCT | IGT ± IFG | 5269; 3 | Placebo Placebo | Rosiglitazone Ramipril | –62e
–9f (NS) | |
IDPP–2 (India) [77] | NRf
| IGT | 407; 3 | Placebo + lifestyle intervention | Pioglitazone + lifestyle intervention | +8 (NS) |
SOS study (Sweden) [78] | RCT | Obese, non-diabetic | 3429; 10 | No surgeryg
| Bariatric surgery | –83 |
5.2 The Diabetes Prevention Program (DPP)
5.2.1 The Randomised Phase of the DPP
5.2.2 The DPP Outcomes Study (DPPOS)
5.2.3 Further Analyses from the DPP Relating to Diabetes Prevention
5.2.4 Effects of Metformin on Cardiometabolic Risk Factors in the DPP
5.2.5 Genetic Markers of Diabetes Risk or Cardiometabolic Outcomes in the DPP
Known association of genes with glucose regulation or effects of treatments | Specific genes or variants | References |
---|---|---|
Mutations that influenced diabetes risk in the DPP | ||
Genes for transporters of metformin |
SLC47A1, LC22A1
| [114] |
AMP kinase or AMP kinase subunits |
STK11, PRKAA1, PRKAA2, PRKAG2
| [114] |
Genes associated with weight loss |
NEGR1 rs2815752 | [115] |
Polymorphisms associated with improved β-cell function |
WFS1
| [116] |
Known diabetes risk allele | TT genotype at rs7903146 in the TCF7L2 genea
| [117] |
Mutations that did not influence diabetes risk in the DPP | ||
Genes influencing glucose regulation: | [118] | |
Fasting glucose |
MTNR1B, G6PC2, GCKR
| |
Impaired β-cell function |
MTNR1B
| |
Increased insulinogenic index |
G6PC2
| |
Ataxia-telangiectasia-mutated geneb
| C allele at polymorphism rs11212617 | [119] |
5.3 The Indian DPP (IDPP)
5.4 The Low-Dose Combination Therapy with Rosiglitazone and Metformin to Prevent Type 2 Diabetes Mellitus (CANOE) Study
6 Other Clinical Evidence for Diabetes Prevention with Metformin
6.1 Systematic Reviews and Meta-Analyses on Diabetes Prevention
6.2 Studies in Insulin-Resistant Adult Populations
6.3 Studies in Paediatric Patients
Location | Main inclusion criteria |
N; duration | Treatments | Key findings |
---|---|---|---|---|
Australia [135] | Obesity (assumed insulin resistance) | 28; 6 months | Placebo vs. metformin 2000 mg/day | Significantly better improvement for metformin vs. placebo in anthropometric indices and fasting insulin |
US [136] | BMI >30, hyperinsulinaemia | 29; 6 months | Placebo vs. metformin 1000 mg/day | Significant improvement in insulin and glucose on metformin |
US [137] | Hyperinsulinaemia | 24; 8 week | Placebo vs. metformin 1700 mg/day | Significant improvements in BMI, body fat, insulin response on metformin |
UK [138] | IGT, IFG | 151; 6 months | Placebo vs. metformin 1500 mg/day | Significant improvements in BMI, FPG and liver function tests on metformin |
Mexico [139] | IGT | 52; 3 months | Placebo vs. metformin 1700 mg/day, each plus lifestyle advice | Significant improvements on metformin in HbA1c, HOMA-IR, resistin |
China [140] | IGT | 30; 3 months | Metformin 1000 mg/day plus lifestyle intervention (no control group) | Significant improvements in BMI, blood pressure, IGT status, lipids, HOMA-IR |
Australia [141] | Obesity, hyperinsulinaemia | Meta-analysis (four studies) | Placebo vs. metformin, each ± standard lifestyle advice | Significant improvement with metformin in HOMA-IR and fasting insulin |
6.4 Obesity/Insulin Resistance Arising as a Consequence of Antipsychotic Therapy
7 Health Economic Aspects of Diabetes Prevention with Metformin
Country | Purpose of the study | Summary of main findings |
---|---|---|
US [81] | Lifetime cost-utility of DPP interventions | ILI and metformin delayed diabetes onset by 11 and 3 years, respectively, and increased life expectancy by 0.5 and 2 years, respectively, due to projected lower incidence of diabetic complications. Cost per QALY vs. placebo was $1100 dollars (ILI) and $31,300 (metformin) for health service perspective, and $8800 dollars (ILI) and $29,900 (metformin) for societal perspective. ILI dominated metformin |
US [157] | Costs of interventions within the randomised phase of the DPP | 3-year cost per subject of metformin relative to placebo: Health system perspective: $2191 (metformin); $2269 (ILI) Societal perspective: $2412 (metformin); $3540 (ILI) Costs inside the trial were lower for placebo vs. other interventions and costs outside the trial were highest for placebo |
US [158] | Within-trial cost effectiveness from health system and societal perspectives | Health system perspective: cost of preventing one case of diabetes vs. placebo—$15,655 (ILI) and $31,338 (metformin); costs per QALY–$31,512 (ILI) and $99,611 (metformin) Societal perspective: cost of preventing one case of diabetes vs. placebo—$24,426 (ILI) and $34,489 (metformin); costs per QALY—$51,582 (ILI) and $99,171 (metformin) |
US [159] | Ten-year evaluation of the cost effectiveness of DPP interventions from the DPP and DPPOS | Total direct medical costs were greater for ILI ($29,164) than metformin ($27,915) or placebo ($28,236). Discounted ICER (health system perspective) was $10,037 for ILI vs. placebo and $13,420 for ILI vs. metformin. Metformin was cost saving vs. placebo |
US [160] | Cost effectiveness of DPP interventions | ILI reduced 30-year diabetes risk in high-risk subjects from 72 to 61 % in an Archimedes model; metformin provided approximately one-third as much long-term benefit as immediate ILI |
Australia, France, Germany, Switzerland, UK [161] | Markov modelling of long-term implications of DPP interventions | ILI and metformin were cost saving vs. placebo in all countries except the UK (+€1021 for ILI and +€378 for metformin at 2002 values). Improvements in life expectancy were 0.35 years for metformin and 0.90 years for ILI |
Australia [162] | Markov model of DPP interventions in Australia | Lifetime incremental direct costs/subject vs. control—$1217 (metformin), and a savings of $289 (ILI). Incremental cost per QALY was $10,142 for metformin. Probability of willingness-to-pay at $50,000 was 78 % (metformin) and 100 % (ILI) |
Germany [163] | Cost effectiveness of ‘real world’ diabetes prevention according to DPP interventions | Metformin and ILI would prevent 42 and 184 cases of diabetes, respectively, of a total number of 14,908 cases of diabetes in a population of 72,500 over 3 years. Costs for ILI were €856,507 (health system perspective) and €4,961,340 (society perspective); costs for metformin were €797,539 (health system perspective) and €1,335,204 (society perspective). ICERs per case prevented for ILI vs. no intervention were €4664 (health system perspective) and €27,015 (societal perspective); corresponding figures for metformin were not provided |
Country | Purpose of the study | Summary of main findings |
---|---|---|
India [164] | Within-trial cost effectiveness in the IDDP | Direct medical costs/subject of interventions: $61 (control); $225 (ILI); $220 (metformin); $270 (ILI + metformin). Incremental cost vs. control of preventing one case of diabetes: $1092 (ILI); $1095 (metformin); $1359 (ILI + metformin) |
Australia [165] | Cost effectiveness of interventions for prediabetes identified during opportunistic screening | Cost/DALY was AUS$22,500 for ILI and AUS$21,500 for metformin vs. no intervention Combining ILI and metformin was not cost effective |
Australia [154] | Modelling of economic output of Australians aged 45–64 years for 1993–2003 | Metformin and ILI both increased the total number of person-days in the workforce (2612 and 3038 days, respectively) and both increased total income (AUS$97,095,000 and AUS$113,049,000, respectively, at 2003 prices), by reducing the incidence of diabetes and associated health problems |
Germany [155] | Cost effectiveness of intervening for screening-detected prediabetes | ICER/QALY vs. no screening for the general screened population was €563 for ILI and €325 for metformin. Interventions were cost saving when ICER was calculated for the group diagnosed with prediabetes |
Canada [156] | 10-year health economics of interventions to prevent diabetes in subjects with IGT | Cases of diabetes prevented among 1000 subjects: 117 (ILI), 52 (metformin), 74 (acarbose). ILI was more effective but increased costs depending on implementation; acarbose and metformin reduced costs by nearly $1000/subject |
US [147] | 10-year health economics of interventions in the DPP and DPPOS | Metformin was cost saving vs. placebo (–$159) or intensive lifestyle intervention (–$2852); ILI was cost saving vs. placebo (–$323). Discounted ICERs (cost/QALY, health system perspective) were $10,037 for ILI vs. placebo and $13,420 for ILI vs. metformin |
US [157] | Cost effectiveness of five screening tests | Costs of tests (random plasma/capillary glucose after 50 or 75 g OGTT, or HbA1c) with subsequent ILI or metformin were $181,000–192,000, which was lower than the cost of no screening ($206,000) |
US [158] | Cost effectiveness of five screening tests | Screening for diabetes and high-risk prediabetes should target patients at higher risk, especially BMI >35 kg/m2, systolic blood pressure ≥130 mmHg, or age >55 years |
8 Metformin in Management Guidelines for Diabetes Prevention
Sponsor | Summary of key recommendations relating to metformin |
---|---|
ADA (US, 2014) [4] | Metformin to be considered in IGT, IFG, HbA1c of 5.7–6.4 %, especially in BMI >35 kg/m2, age <60 years or prior GDM |
ADS/ADEA (Australia, 2007) [171] | Consider pharmacologic management of prediabetes after a 6-month trial of lifestyle intervention |
ALAD (Latin America, 2011) [172] | First step is lifestyle management; if not sufficient and/or in additional risk factors, pharmacological treatment (e.g. metformin) is recommended |
CDA (Canada, 2013) [173] | Implement intensive lifestyle intervention to prevent type 2 diabetes; metformin may reduce the risk of type 2 diabetes in subjects with IGT |
ESC/EASD (Europe, 2013) [10] | Strong emphasis on healthy lifestyle for diabetes prevention but no specific management recommendations are provided |
European Expert Group (2013) [34] | Strong emphasis on lifestyle intervention, use metformin or acarbose second-line (subject to tolerability) in people with IGT, or orlistat second-line in obese subjects |
Ministry of Health (Chile, 2010) [174] | Use metformin if lifestyle change is insufficient or in patients with risk factors |
IDF (Global, 2006) [175] | Use metformin 250–850 mg/day where lifestyle intervention is insufficiently effective in reducing body weight and improving glucose tolerance |
IMSS (Mexico, 2009) [176] | In addition to lifestyle change, metformin or acarbose are recommended to decrease the risk of developing diabetes |
International expert group (2008) [177] | Priority given to lifestyle management over pharmacologic therapy for patients at increased risk of type 2 diabetes or cardiovascular disease |
MEMS (Malaysia, 2009) [178] | Metformin to be considered in patients with additional risk factors or if lifestyle change alone is not sufficient |
MSC (Spain, 2008) [179] | In addition to lifestyle change, treatment with metformin, acarbose or pioglitazone is mentioned |
RVEM (Venezuela, 2012) [180] | First step is lifestyle management; if not sufficient and/or in additional risk factors, pharmacological treatment (e.g. metformin) is recommended |
SBD (Brazil, 2011) [181] | In addition to lifestyle change, treatment with metformin (preferable) or, alternatively, acarbose or pioglitazone is mentioned |
SPE (Peru, 2012) [182] | Alter lifestyle change, metformin is recommended as second-line treatment |
TEMD (Turkey, 2013) [183] | After lifestyle change as first-line, treatment with metformin(preferable) or other oral antidiabetic drugs as second-line is mentioned |
World Health Organization (Global, 2006) [184] | Highlights results of the DPP (including with metformin and the DPS for diabetes prevention; the main focus is on improved lifestyle |